Sign in / Join Now
ETFs & Funds
Active Biotech AB
- Grey Market
What's your position on
Why are you
Posts appear on the
page of subscribers to this ticker
Active Biotech AB reports Q4 results
Thu, Feb. 18
Patient enrollment complete in (yet another) late-stage study of laquinimod in RRMS
Jun. 25, 2015
Active Bio and Ipsen call it quits in prostate cancer
Apr. 16, 2015
Teva expands laquinimod clinical development
Nov. 4, 2014
Teva's (TEVA -1.8%) and Active Biotech's (ATVBF.PK) oral laquinimod drug improved renal function...
Jun. 12, 2013
Teva (TEVA +0.25%) and Active Biotech (ATVBF.PK) say that early treatment of Multiple Sclerosis...
Mar. 21, 2013
Laquinimod, which is being developed by Teva (TEVA +1.2%) and Sweden's Active Biotech, performed...
Oct. 22, 2012
Teva (TEVA) and Active Biotech are set to initiate the third Phase III trial of their oral...
Aug. 8, 2012
Teva (TEVA +5.6%) and Active Biotech (ATVBF.PK) announce their Phase III study of laquinimod, a...
Dec. 9, 2010
Visit Seeking Alpha's
New Earnings Center
Currently, there's no company description for ATVBF.
Other News & PR
See More »